If you are passionate about ending breast cancer and have an interest in scientific research, we welcome you to join us. Komen’s research advocates, or Advocates In Science may be men or women, laypersons or healthcare professionals, Komen Affiliate members, or individuals involved in advocacy with other breast cancer organizations. While many advocates are breast cancer survivors or have a loved one affected by the disease, this is not a requirement. The most important qualification is an ongoing commitment to improving the lives of those with breast cancer or those at risk for breast cancer. All applicants should demonstrate a desire to learn about breast health, breast cancer research and breast cancer issues while representing a broader perspective of those people affected by breast cancer. Applicants are strongly encouraged to be active with their local Affiliate of Susan G. Komen®. Learn more about our Advocates in Science here.
If you would like to be part of this community, please complete the online membership form. Once you have completed the membership form, please select an individual to complete a referral form on your behalf. We review membership forms and accept new members on a rotating basis. If you have questions, please email firstname.lastname@example.org.
As a research advocate, you are strongly encouraged to submit a Statement of Commitment to the scientific research team when you begin working with them. This statement helps researchers understand your level of commitment and expertise and will aide in defining your role in the research project. Below is an example of a Research Advocate Statement of Commitment.
Advocate Physical Address, Phone Number and Email Address
Susan G. Komen
5005 LBJ Freeway, Suite 250
Dallas, TX 75244
Dear Komen Reviewers:
It is with great enthusiasm that I write this statement of commitment for the Komen Investigator-Initiated Research grant proposal submitted by Dr. John Doe, entitled "Exciting New Research in the Fight Against Breast Cancer.” I would be honored to serve as an advocate consultant for this important project.
This research project focuses on identifying molecular alterations that may drive the progression of DCIS to invasive breast cancer, which is an extremely important topic because it represents an opportunity to prevent a common and essentially "harmless" disease from developing into a potentially lethal disease. I believe that this research may provide the potential to avoid unnecessary mastectomies and suffering in those women where DCIS has a small likelihood of becoming invasive breast cancer. In addition, health care resources could be better utilized and many dollars saved if unnecessary treatment is not provided.
As an eight-year breast cancer survivor, and a founding member and co-chair of the Research Advocacy Committee at Komen Any Town affiliate, I have a strong interest in supporting breast cancer research by providing my expertise as a patient and survivor. I am deeply interested in all aspects of breast cancer research (from prevention to detection and treatment) and, as an advocate, have worked closely with investigators in the Breast Cancer Research Program at The University School of Medicine. Over the past two years, I have collaborated with researchers in developing pre-applications and applications for Komen national grants, as well as for Department of Defense Congressionally Directed Medical Research Program grants supporting breast cancer research. I have served on peer review panels for Komen National and the DoD for the last four years. This experience positions me to play an active and important role on the project team for this Promise Grant research project.
Dr. Doe and his team members have demonstrated a strong interest in patient advocate participation during the development of the pre-application and application for this project. Upon funding, I will continue to collaborate with Dr. Doe and his team to represent the patient perspective throughout the term of the grant. I will collaborate during the evolution of the project by meeting with the PI and his team, and by providing review and commentary from the patient perspective on the investigators’ progress reports and publications.
I am convinced that this research will lead to the discovery of molecular reasons for the progression of DCIS to invasive breast cancer. It is critical to learn how to prevent DCIS from becoming invasive in order to prevent overtreatment and unnecessary suffering due to the side effects patients experience while being treated. It is an honor to support Dr. Doe and his team who have demonstrated their belief in the value of involvement of patient advocates in the formulation, design and translation of this research to ensure the greatest value to the patient community. I look forward to continuing to be an active member of this team. Thank you for your consideration.
A biographical sketch—also known as a biosketch—is an abbreviated CV written in a specific format (e.g., NIH format) that summarizes your professional and educational accomplishments, publications and research advocacy experience. They are used to highlight important aspects of your training, experiences, and interests that may help researchers determine if you are a good fit for a particular project. Below are two examples of research advocate biosketches. A blank form of the template is provided by the National Institutes of Health and can be found here.
Download a PDF of this biosketch example here.
Provide the following information for the Senior/key personnel and other significant contributors. Follow this format for each person. DO NOT EXCEED FOUR PAGES.
Breast Health Advocate
eRA COMMONS USER NAME (credential, e.g., agency login)
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing; include postdoctoral training and residency training if applicable.)
INSTITUTION AND LOCATION
FIELD OF STUDY
University of City
University of State
Download a PDF of this biosketch example here.
OMB No. 0925-0001/0002 (Rev. 08/12 Approved Through 8/31/2015)
Cancer Research Advocate
advocate abbreviation (if applicable)
State University, City, State
A. Personal StatementI am currently an active advocate for cancer research and clinical trials. I am devoted to science and have a Bachelor’s of Science degree in biology/microbiology and extensive laboratory experience in molecular biology. I am also a 14-year survivor of breast cancer. The inquisitive nature of being a scientist and having an understanding of scientific concepts along with my personal experience through cancer treatment (including 2 clinical trials) fits well with being a cancer research advocate. As an advocate on a research projects, I can bring an outside perspective and add urgency to the translational potential of the project. Scientific endeavors are exciting, but they have to be done with an outcome that benefits patients. My goal through research advocacy is to further my contribution into the conduct of research as well as the design and implementation of clinical trials that brings the best research to the clinic to benefit patients.B. Positions and HonorsPositions and Employment1984-1986 Research Technician III, State University, Coll. of Vet. Med.1986-1987 Research Assistant II, Medical School1987-1990 Research Assistant, University1991-1992 Research Associate I, Research Center1992-1994 Research Associate II, Research Center1994-1997 Scientist, Research Center1997-2001 Research Scientist, State University, Coll. of Vet. Med.2001-2007 Research Technician III, State University, Coll. of Vet. Med. 2007-present Research Specialist, Advanced, State University, Coll. of Vet. Med.Other Experience and Professional MembershipsMicrobiology and North Carolina State University1992-present American Society for Microbiology2006-2008 Staff Senator, District 32008 Nomination Committee for Vice Chancellor of Research and Graduate Studies2008-2010 Lecturer, Senior Rotation in Microbiology VMP9772006-present Laboratory Teaching Assistant, Pathogenic Bacteriology and Mycology, VMP914/9102008-2012 Guest Laboratory Lecture, Pathogenic Bacteriology and Mycology VMP914, Molecular Diagnostic Microbiology2013 North Carolina State University, College of Veterinary Medicine, Award for Excellence2013-present Staff Senator, District 3Cancer Research2001 – 2005 NC Triangle Affiliate Susan G. Komen for the Cure, Board Member, Chair, Education Committee. 2003 – 2008 Triangle Breast Cancer Support Group, Facilitator2003 – present Komen Research Grants Program, Advocate Reviewer, 2003 National Breast Cancer Coalition, Project LEAD® Graduate2005 – present Duke Comprehensive Cancer Center, Cancer Protocol Committee, Advocate Reviewer2005 – 2012 National Cancer Institute, Cancer Biomedical Informatics Grid (caBIG™), Advocate2005 – 2007 Congressionally Directed Medical Research Programs (CDMRP), Breast Cancer Research Program, Consumer Reviewer2005 – 2009 Duke Comprehensive Cancer Center, Breast Cancer SPORE, Advocate2006 – 2007 Patient Advocate Research Team, Advisory Committee Member2006 – 2010 Duke Comprehensive Cancer Center, Executive Committee, Member2007 Komen Focus Area Research Grants Program, Dallas, Reviewer and Programmatic Committee Member2007 American Association for Cancer Research, Scientist<->Survivor Program participant2007 “How to be an Advocate for Cancer Patients” Conference, Conference Committee Chair2008 Komen Promise Grants, Reviewer and Executive Committee Member2008-present The Alliance for Clinical Trials in Oncology (CALGB), Advocate, Breast Committee Member; Co-vice Chair, Patient Advocate Committee2008-2013 Translational Breast Cancer Research Consortium, Advocate Member2008-present Susan G. Komen for the Cure, Steering Committee for Advocates in Science2009-present Duke Cancer Institute, Office of Health Equity and Disparities, Community Advisory Council, Member 2009-2013 NCI, Breast Cancer Steering Committee, Member2009-2013 NCI, Patient Advocate Steering Committee, Member 2009-present NCI, Consumer Advocates in Research and Related Activities (CARRA), Member 2010-present Susan G. Komen for the Cure, Komen Scholar, Scientific Advisory Council, Advocate Member2011 NCI, PROSPR Grant Review Panel, Advocate Member2011-present Susan G. Komen for the Cure, A2SPIRE Working Group, co-Chair 2012-present The Alliance for Clinical Trials in Oncology, Patient Advocate Committee, Vice-chair2012-present Department of Defense, Transformative Vision Award, H.K. Lyerly PI, Advocate2012-2013 ASCO-CAP HER-2 Testing in Breast Cancer Guideline, Panel Member2012-present NCI, BCSC, ER+ Breast Cancer Working Group, Member2013 Duke Cancer Institute, Translational Aspects of Pathobiology, Patients Advocates in Research, Lecturer2013-present John’s Hopkins Sidney Kimmel Comprehensive Cancer Center, Breast Cancer SPORE, External Advisor2013 FDA/ASCO/AACR, Innovations in Breast Cancer Drug Development, Neoadjuvant Breast Cancer Workshop, Panel Participant2013 Susan G. Komen for the Cure Tissue Bank Think Tank, Participant2013-present Susan G. Komen for the Cure, Steering Committee, co-Chair2013-present ASCO Breast Cancer Consensus Panel, Member2013-present Patient Centered Outcomes Research Institute, Stakeholder Reviewer2013-present U. S. Food and Drug Administration, Patient Representative
C. Selected Peer-reviewed Publications (Selected)
Cancer AdvocacyAdvocate 2002. Breast cancer prevention through the eyes of a survivor. Environ. Mol. Mutagen. 39:108-111. [PMID: 11921177]Advocate2011. Phase 0 Clinical Trials: Taking Advantage of a “Window of Opportunity” in Breast Cancer. Breast Disease Quarterly. 22(3):252-4. [http://dx.doi.org/10.1016/j.breastdis.2011.06.054]Shapira I., T. Deshields, D. Kroetz, P. Friedman, Advocate, D. Collyar, L. N. Shulman, M. M. Bertagnolli, L. Dressler and J. Peppercorn. 2012. Ethical Aspects of Participation in the Database of Genotypes and Phenotypes (dbGaP) of the National Center for Biotechnology Information (NCBI): The CALGB experience. Cancer. Oct 15;118(20):5060-8. [PMID: 22415847]Wolff, A.C., M.E.H. Hammond, D.G. Hicks, M. Dowsett, D.C. Allred, J.M.S. Bartlett, M. Bilous, P. Fitzgibbons, W. Hanna, R.B. Jenkins, P.B. Mangu, L.M. McShane, S. Paik, E.A. Perez, M.F. Press, Advocate, G.H. Vance, G. Viale and D.F. Hayes. 2013. Recommendations for Human Epidermal Growth Factor Receptor Testing in Breast Cancer: American Society of Clinical Oncology - College of American Pathologists (ASCO/CAP) Clinical Practice Guideline Update. J. of Clin. Oncol. (accepted)Scientific (selected)Orndorff, P.E., Advocate, D. Schauer, S. Falkow. 1985. Two Modes of Control of pil A, the Gene Encoding Type 1 Pilin in Escherichia coli. J. of Bacteriol. 164:321-330. [PMID: 3930469]Advocate, D. Schauer, P.E. Orndorff. 1986. Metastable Regulation of Type 1 Piliation in Escherichia coli and Isolation and Characterization of a Phenotypically Stable Mutant. J. of Bacteriol. 168:179-185. [PMID: 3019997]Taylor, R., C. Shaw, K. Peterson, Advocate, and J. Mekalanos. 1988. Safe, live Vibrio cholerae Vaccines? Vaccine 6:151-154. [PMID: 2898843]Nasim, F.H., Advocate, H.M. Hoffmann, H. Kuo, P.J. Grabowski. 1990. A Sequential Splicing Mechanism Promotes Selection of an Optional Exon by Repositioning a downstream 5' Splice Site in Preprotachykinin pre-mRNA. Genes and Development 4:1172-1184. [PMID: 2210374]Walker, G.T., J.G. Nadeau, Advocate, J.L. Schram, C.M. Nycz and D.D. Shank. 1994. Multiplex Strand Displacement Amplification (SDA) and detection of DNA sequences from Mycobacterium tuberculosis and other Mycobacteria. Nucleic Acids Res. 22:2670-2677. [PMID: 8041630]Advocate, C.P. Linn, D.L. Woodard and G.T. Walker. 1997. Simultaneous Strand Displacement Amplification and Fluorescence Polarization Detection of Chlamydia trachomatis DNA. Analytical Biochemistry. 247:130-137. [PMID: 9126382]Advocate, L.M. Temple and P.E. Orndorff. 2000. A role for lipopolysaccharide in turkey tracheal colonization by Bordetella avium as demonstrated in vivo and in vitro. Mol. Microbiol . 36:1425-35 [PMID: 10931292]Advocate, L.M. Temple, D.M. Miyamoto, D.J. Maskell and P.E. Orndorff. 2003. Unsuspected Similarities Between Bordetella avium and other Pathogenic Bordetella. Infect. Immun. 71:2591-2597. [PMID: 12704133]Advocate, M.M. Suyemoto, A.M. Palermo, J.R. Horton, T.S. Hamrick, E.A. Havell and P.E. Orndorff. 2008. A Listeria monocytogenes Mutant Defective in Bacteriophage Attachment Is Attenuated in Orally Inoculated Mice and Impaired in Enterocyte Intracellular Growth. Infect. Immun. 76:4046-4054. [PMID: 18559424]Lee S.M., A. Wyse, A. Lesher, M.L. Everett, L. Lou, Z.E. Holzknecht, J.F. Whitesides, Advocate, D.E. Bowles, S.S. Lin, S.L. Tonkonogy, P.E. Orndorff, R.R. Bollinger and W. Parker. 2010. Adaptation in a mouse colony monoassociated with Escherichia coli K-12 for more than 1,000 days. Appl Environ Microbiol. 76(14):4655-63. [PMID: 20472724]Suyemoto M.M., Advocate, T.S. Hamrick, J.A. Barnes, E.A. Havell, and P.E. Orndorff. 2010. Factors associated with the acquisition and severity of gestational listeriosis. PLoS One 5:e13000. [PMID: 20885996]Spears P.A., M.M. Suyemoto, T.S. Hamrick, R.L. Wolf, E.A. Havell, and P.E. Orndorff1. (2011) In Vitro Properties of a Listeria monocytogenes Bacteriophage Resistant Mutant Predict its Efficacy as a Live Oral Vaccine Strain. Infect Immun. 79(12):5001-9. [PMID: 21930759]Suyemoto, M.M., T.S. Hamrick, Advocate, J.R. Horton, I.M. Washington, E.A. Havell, L.B. Borst and P.E. Orndorff. (2013) Extrauterine Listeriosis in the Gravid Mouse Influences Embryonic Growth and Development. PLoS ONE. (accepted)D. Research SupportN/A